Angioedema with acquired/sporadic C1 INH deficiency. Andrea Zanichelli, Milan (Italy) Jonathan Bernstein, Cincinnati (USA)
|
|
- Godwin Washington
- 6 years ago
- Views:
Transcription
1 Angioedema with acquired/sporadic C1 INH deficiency Andrea Zanichelli, Milan (Italy) Jonathan Bernstein, Cincinnati (USA)
2 Outline Definition Systematic Literature Search Prevalence Pathophysiology Case presentation Diagnosis Treatment Angioedema with acquired/sporadic C1 INH deficiency Questions to discuss
3 Definition: to be discussed Acquired Angioedema (AAK) Angioedema with acquired C1 INH deficiency Angioedema with sporadic C1 INH deficiency Non hereditary C1 INH deficiency angioedema Acquired C1 INH deficiency syndrome
4 1 Systematic Literature Search: Aquired Angioedema We searched in Pub Med for the following terms: angioedema or C1 inhibitor protein or C1 inhibitor. AND we matched these results with the following terms: acquired or sporadic or non hereditary. We found 397 results.
5
6 Literature Search Methods From 397 titles we excluded non-english papers and those not related to acquired C1 INH deficiency angioedema (i.e. urticaria, acquired angioedema due to allergy, hereditary angioedema, non angioedema symptoms) or full text not available. 117 papers were included in the review: - 24 reviews on angioedema including AAE - 78 case reports/case series - 14 observational studies - 1 clinical trial
7 Prevalence of AAE No epidemiologic study, prevalence unknown 180 pts with AAE reported in literature Prevalence of AE in the general Danish population (18-69) was 7.4% (Madsen Acta Derm Venereol 2012). Prevalence of HAE: Bygum A Br J Dermatol 2009: minimal prevalence of HAE in Denmark is 1,4: Usual estimated prevalence of HAE between 1:10,000 and 1:50,000 (Zuraw NEJM 2008) Milan population: 1 AAE patient for every 10 HAE patients (Cicardi and Zanichelli A Allergy, Asthma & Clinical Immunology 2010; Cicardi M Acta Haematol 2012)
8 Genetics Is AAE associated with mutations of C1 INH gene or impaired synthesis of functional C1 INH?
9 2 Systematic Literature Search: Genetics In Pub Med Advanced Search Builder, we entered the following search terms: angioedema AND genetics (MeSH Subheading) AND acquired or sporadic or non hereditary We found 89 results
10
11 2 Systematic Literature Search: Genetics None of the abstracts included research on the genetics of acquired angioedema
12 Pathophysiology. Mechanism of C1 INH deficiency The C1 INH deficiency is thought to be due to either/both: An underlying lymphoproliferative disease leading to hyperactivation of the classical complement pathway (i.e., lymphoma) Autoantibodies to C1INH resulting in depletion of C1INH Increased catabolism of C1 INH leads to hyperactivation of classic complement pathway and consumption of C1 (Zingale Immun Allergy Clin N Am 2006)
13 Associated lymphoproliferative diseases AAE was first reported in the presence of lymphoma in (Caldwell JR Clin Immunol Immunopathol 1972) We found 47 subsequent studies that confirmed this association and also reported association with MGUS Zingale Immun Allergy Clin N Am 2006 reported a prevalence of MGUS in 35% of AAE, higher than the 3% observed in general population Mechanism of C1 INH deficiency is thought to be due to massive lymphocytic activation of classical complement pathway or to direct action on C1 INH (Cugno Trends in Molecular Medicine 2009)
14 Autoantibodies to C1 INH On the basis of initial findings of autoantibodies to C1 INH in otherwise healthy patient (Jackson et al Nature 1986; Alsenz J et al NEJM 1987), AEE was divided in type I, associated with lymphoproliferative disease, and type II, caused by autoantibodies to C1INH. Because lymphoproliferation and autoimmunity coexist in most patients and may induce one another it is difficult to distinguish different types of AAE (Cicardi M Medicine 2003; D Incan M Dermatology 1999; Whaley K Clin Exp Immunol Dec 1996, Zingale LC et al. Immun Allergy Clin N Am 2006)
15 Associated diseases in 30 AAE pts SLE: 5 pts (Cacoub Arthriti Rheum2001, Ochonisky Dermatology 1993, Nettis Eur J Clin Invest 2005) Autoimmune Haemolytic Anemia: 1 pt (Hauptmann G Blut 1976) Cryoglobulinemia: 2 pts (Mandle J Immunol 1994; Casali P Acta Haematol 1978) Rheumatoid Arthritis: 1 pt (Fremeaux-Bacchi VAm J Med 2002) Sjogren s syndrome: 1 pt (Sanchez-Cano D Lupus 2008) Anticardiolipin antibodies: 2 pt (Di Leo E Int J Immunopathol pharmacol 2011; Szeplaki G Int Arch Allergy Immunol 2008) Neoplasms: 9 pts (Fremeaux-Bacchi Am J Med 2002; Cicardi Medicine 2003; Wasserfallen J Allergy Clin Immunol 1995; Cohen J Allergy Clin Immunol 1978; Alonso Acta Anaesthesiol Scand 2002; Van Spronsen Net J Med 1998; Spath Aech Intern Med 1989) Infectious disease: Echinococcus 2 pts, Helicobacter pylori 3 pts Thrombotic disorder 3 pts Leucocytoclastic vasculitis1 pt (Farkas Acta Derm Venereol 2001) No associated diseases: 20 pts out of 180
16 Pathophysiology. Mediators In 4 AAE patients during remission plasma bradykinin concentration was higher compared to healthy volunteers and further increased during acute attacks (Nussberger J Lancet 1998) AAE is similar to HAE, where inappropriate activation of a C1INH-deficient contact-kinin system releases excess bradykinin, resulting in edema (Davis AE Annu Rev Immunol 2004, Cugno Trends in Molecul Medicine 2009)
17 Case Presentation A 59 yo WF with hx of angioedema presents with recurrent abdominal pain and two throat swelling episodes; no family history of AE Screening C4 level < 2 mg/dl Further testing revealed a C1INH function = 1%, C1INH quantitative=9 mg/dl (nl=21-39 mg/dl), C1q =50ug/ml (nl= ) C1INH Ab = 14,283.8 (245.3% of standard normal =.89-36) CBC with diff, SPEP, UIE normal Bone marrow biopsy normal Due to precedence (Donaldson VH, et.al. J Lab Clin Med 1992; 119: ) patient was started on plasmapheresis x 5 followed by cytoxan treatments x 6. Tolerated well without significant side effects 3 month follow-up no symptoms since last August. She has completed 5 plasmapheresis treatment and cytoxan x 6 without complications. C1INH Ab decreased to 15.2 after 3 months (normal range is <36) Six month follow up still asymptomatic; repeat C1INH Ab pending
18 Diagnosis. Clinical Characteristics Age of onset > 40 y.o. 94% of pts (Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010) Facial, tongue, and uvular swelling prominent (Bouillet-Claveyrolas Am J Med 2003; Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010) GI swelling less common than HAE less than 50% of pts (Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010) 30% of pts (Bouillet-Claveyrolas Am J Med 2003, Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010) Upper airway edema: 50% of AAE pts (Breitbart Allergy Asthma Proc 2010, Bouillet-Claveyrolas Am J Med 2003) No family history of AE
19 NL = Normal Complement levels in the differential diagnosis of Angioedema
20 Laboratory testing C1INH function and antigen and C4 below 50% of normal (Agostoni J allergy Clin Immunol 2004; Zingale Immunol Allergy Clin N Am 2006; Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010) Temporary normalization of one of these parameters has been reported (Spath Arch Intern Med 1989). Low C1q 70% of pts (Cicardi Allergy Asthma Clin Immunol 2010) review of the 168 cases of AAE shows that the C1q value is normal in 10 cases and diminished in 94 cases (Breitbart Allergy Asth Proc 2010) Presence of anti-c1inh antibodies in 71 pts out of 136 (Zingale Immunol Allergy Clin N Am 2006). tested only in few specialized research lab!
21 Falsely normal C4 in a case of acquired C1 esterase inhibitor deficiency (McLean-Tooke A J Clin Pathol 2007) A 59-year-old lady presented with recurrent AE without urticaria. The clinical history and examination were consistent with an acquired C1 esterase deficiency secondary to lymphoproliferative disease (splenic marginal lymphoma). C4 level assayed by nephelometry on automated analyser was normal. Analysis using different nephelometric analysers revealed consistently low C4, despite consistent normal readings in the analyser used from the authors. Further investigation revealed an IgM-k paraprotein that seemed to interfere with both this and haematology coagulation assays. Conclusion: monoclonal paraproteins may interfere with nephelometric, turbidimetric and immunological assays in a non-antibody- specific manner and should be considered when there are unusual or unexpected results, particularly in a patient with lymphoproliferative disease.
22 Is C1q a reliable marker for AAE? Yamamoto T et.al. Am J Med Sci 2012;343(3):
23 HAE patients can develop low C1q: a case report 51 y/o female HAE patient with normal C1q since age 12 developed worsening symptoms C1q level was found to be very low CBC and bone marrow biopsy revealed follicular lymphoma Guilarte, M et.al. J Investig Allergol Clin Immunol 2008; 18: Bernstein has found a similar case of a 31 year old WM with HAE since childhood who developed CML coinciding with worsening attacks and a low C1q level
24 Unusual Cases of AAE AAE patients may not have low C1q level and/or anti-c1 inhibitor antibodies. Genetics can distinguish between AAE and de novo HAE Zuraw B, Bernstein JA, Lang D. A Focused Parameter Update: Hereditary Angioedema, Acquired C1 Inhibitor Deficiency, and ACE-Inhibitor Associated Angioedema 2012, JACI (in press).
25 Additional clinical evaluation Complete blood count with differential Erythrocyte sed rate, C-reactive protein Serum protein electrophoresis Urine analysis for light chain proteins Bone marrow biopsy?
26 Rituximab. Review of 14 AAE pts with lymphoproliferative disease and /or ant-c1 INH autoantibodies Rituximab in 14 AAE pts with lymhoproliferative disease (lymphomas and MGUS) and/or anti-c1inh autoantibodies Branellec A J Clin Immunol 2012: 7 pts, follow up of 6-24 months 2 with no subsequent attacks,1 very rare attack 2 with partial response: 1pt less severe symptoms and 1 pt less frequent attack 2 with initial benefit with regression of symptoms after several months Lam J Clinical Oncology: 1 pt, 8 months follow up Clinical improvement, no subsequent attacks Hassan A Acta Derm Venereol 2011: 1 pt, follow up 2 y.o. Clinical improvement : less frequent and mild attacks Sanchez-Cano D Lupus 2008: 1 pt, follow up 11 months Initial clinical response, relapse after 3 months. Additional course of Rituximab with no subsequent attacks Levi M Am J Med 2006: 3 pts, follow up 8-10 months clinical improvement and no AE symptoms Ziakas PD Haematologica 2004: 1 pt, follow up 6 months Less severe and less frequent symptoms
27 Plasmapheresis and cyclophoshamide for treatment of AAE Donaldson (J Lab Clin Med, 1992) repoted 1 pt with anti-c1inh autoantibody treated with plasmapheresis and additional treatment with cyclophosphamide with sustained remission. Bernstein JA et.al. has recently treated 3 patients with this regimen without side effects and sustained remission (not published as of yet)
28 Treatment of Acute attacks On demand therapy Replacement therapy with pdc1inh (2000 UI) partially or completely non-responsive pts to pdc1inh treatment (Agostoni A J allergy Clin Immunol 2004; Zanichelli Allergy 2012) Icatibant 11 pts successfully treated with Icatibant (Zanichelli Allergy 2012; Zanichelli A Intern Emerg Med 2011; Bygum A Acta Derm Venereol 2011; Weller K J Eur Acad Dermatol Venereol 2011; Bright P Clin Exp Dermatol 2010) Ecallantide 2 pts successfully treated with Ecallantide (Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010)
29 Prophylaxis Anti-fibrinolytics (tranexamic acid, epsilon aminocaproic acid) Better efficacy than in HAE first choice drug for prophylaxis (Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010) Androgens less effective than in HAE (Agostoni A J allergy Clin Immunol 2004;Cicardi and Zanichelli Allergy Asthma Clin Immunol 2010) Pd C1 INH Prevention of attacks with pd C1 INH 1000UI every 5-7 days in 3 pts (Bork J Allergy Clin Immunol 1989, Levi J Allergy Clin Immunol 2006)
30 Discussion/Consensus (hopefully!)
31 Name of Angioedema Acquired Angioedema with C1 INH deficiency (AAE C1INH)
32 No family history of AE Clinical Diagnosis Late age of onset usually above 40 y/o Facial, tongue, and uvular swelling more common than HAE Frequently associated with B cell lymphoproliferative disease (including MGUS) and/or autoantibodies to C1INH
33 Laboratory Diagnosis Low C1INH function (below 50% of lower limits of normal using chromogenic assay) and low C4 Low C1q found in majority of patients Presence of anti-c1inh antibodies in majority of patients Genetic testing to exclude HAE when diagnosis is inconclusive Laboratory testing including CBC with differential, WSR, serum protein electropheresis Further work-up as appropriate to exclude other associated diseases Refer to a hematologist/oncologist Flow cytometry for lymphocyte populations Bone marrow biopsy
34 Therapeutic approach Burden of disease vs. Harm of treatment Treatment of underlying disease if appropriate Consult with hematologist/oncologist if evidence of underlying lymphoproliferative disease Treatment of angioedema as appropriate On-demand therapy (icatibant, ecallantide) for angioedema attacks Prophylaxis therapy for frequent angioedema attacks (tranexamic acid, attenuated androgens) Treatment with on-demand or prophylaxis C1INH may be not be effective in some cases because of potential risk of immunogenicity; long term risk vs. benefits is currently unknown Reconsider treating the underlying disease if angioedema poorly controlled
Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate
Bork et al. Orphanet Journal of Rare Diseases (2019) 14:65 https://doi.org/10.1186/s13023-019-1043-3 RESEARCH Open Access Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with
More informationTakhzyro (lanadelumab-flyo)
Takhzyro (lanadelumab-flyo) Policy Number: 5.01.675 Last Review: 1/2019 Origination: 1/2019 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Takhzyro
More informationANGIOEDEMA WHAT YOU NEED TO KNOW
ANGIOEDEMA WHAT YOU NEED TO KNOW K I MBERLY HULL DO No relevant disclosures OBJECTIVES Review the etiologies of angioedema without urticaria Discuss the diagnostic approach to angioedema Discuss acute
More informationThe Journal of Angioedemasit amet
Hereditary Angioedema with Normal C1 Inhibitor Response to Progesterone Therapy: A Case Report and Review of the Literature. James Kuhlen MD 1,2, Ami Mehra MD 3, and Michelle Conroy MD 1, 2 1 Massachusetts
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hereditary Angioedema Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hereditary Angioedema (Berinert, Cinryze, Firazyr, Haegarda, Kalbitor, Ruconest,
More informationUpdate on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema
Update on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema Ashley Frazer-Abel, Ph.D., 1 and Patricia C. Giclas, Ph.D. 2 ABSTRACT The importance of
More informationAngioedema. Disclosures. Question #1. Objectives. Question #3. Question #2 12/28/2015. Differentiate the various angioedema subtypes
None Disclosures Jason Knuffman, M.D. Allergy and Clinical Immunology Quincy Medical Group Unity Point Health System Quincy, IL Objectives Question #1 Differentiate the various angioedema subtypes Identify
More informationHAE disease fact sheet
[Insert organization logo and the hae day :-) logo] HAE disease fact sheet Hereditary Angioedema (HAE) is a rare, potentially life threatening inherited disorder with symptoms of severe, painful, and recurring
More informationHAE with normal C1-INH (HAE type III, HAE-III) Konrad Bork, MD Department of Dermatology Johannes Gutenberg University, Mainz Germany
HAE with normal C1-INH (HAE type III, HAE-III) Konrad Bork, MD Department of Dermatology Johannes Gutenberg University, Mainz Germany Mainz 1985 Observation of a family Seven women (no man!) had relapsing
More informationLifting the Veil on a Potentially Fatal Disease. May 28, Grand Hyatt New York New York, NY. Educational partner, RMEI, LLC
ANGIOEDEMA: Lifting the Veil on a Potentially Fatal Disease May 28, 2014 Grand Hyatt New York New York, NY Educational partner, RMEI, LLC Session 2: Rare Cases in Angioedema: Lifting the Veil onn a Potentially
More informationAngioneurotic edema. Author: Doctor Laurence Bouillet 1 Creation Date: April 2001 Updates: December 2002 June 2003 February 2005
Angioneurotic edema Author: Doctor Laurence Bouillet 1 Creation Date: April 2001 Updates: December 2002 June 2003 February 2005 Scientific Editor: Professor Loïc Guillevin 1 Service de médecine interne
More informationSelf-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency
Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD, a Goda Choi, MD, a Charles Picavet, MA, b and C. Erik
More informationRecurrent Angioedema and the Threat of Asphyxiation Konrad Bork
REVIEW ARTICLE Recurrent Angioedema and the Threat of Asphyxiation Konrad Bork SUMMARY Background: Recurrent angioedema may affect the skin or, less commonly, the tongue, gastrointestinal tract, and larynx.
More informationSubject: Ruconest (C1 esterase inhibitor [recombinant]) Original Effective Date: 1/13/15. Policy Number: MCP-233 Revision Date(s): 12/13/17
Subject: Ruconest (C1 esterase inhibitor [recombinant]) Original Effective Date: 1/13/15 Policy Number: MCP-233 Revision Date(s): 12/13/17 Review Date: 12/15/2016 DISCLAIMER This Medical Policy is intended
More informationSporadic Antihistamine-Resistant Angioedema Potential Pathophysiological Mechanisms
Sporadic Antihistamine-Resistant Angioedema Potential Pathophysiological Mechanisms Massimo Triggiani, MD, PhD Division of Allergy and Clinical Immunology University of Salerno HAWK Consensus Meeting Gargnano,
More informationHereditary angioedema (HAE) is a rare but potentially
Severity of Hereditary Angioedema, Prevalence, and Diagnostic Considerations Jonathan A. Bernstein, MD Hereditary angioedema (HAE) is a rare but potentially life-threatening disease affecting approximately
More information:: Non histamine-induced angioedema
:: Non histamine-induced angioedema This document is a translation of the French recommendations drafted by Dr. Laurence Bouillet, reviewed and published by Orphanet in 2009. - - Some of the procedures
More informationComparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12910 Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey H. J. Longhurst,*
More informationOptimizing Screening and Management of the Patient with Hereditary Angioedema: A Primer for Primary Care Practice
Optimizing Screening and Management of the Patient with Hereditary Angioedema: A Primer for Primary Care Practice Learning Objectives After participating in this educational activity, participants should
More informationWhen is prophylaxis for hereditary angioedema necessary?
Review When is prophylaxis for hereditary angioedema necessary? Timothy Craig, DO*; Marc Riedl, MD ; Mark S. Dykewicz, MD ; Richard G. Gower, MD ; James Baker, MD ; Frank J. Edelman, MD ; David Hurewitz,
More informationTreatment regimens. Single IV infusion of pdc1 INH at a dose of 10 or 20 U/kg, or placebo, for a single abdominal or facial attack (not laryngeal)
Annex 1 Letters supporting the application (separate document) Annex 2 Pivotal clinical trials (and extension studies) evaluating for treatment of acute HAE attacks Reference Study type Patients Treatment
More information2018 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTreatment of Waldenström s Macroglobulinemia Mayo Consensus
Treatment of Waldenström s Macroglobulinemia Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Mayo Clinic
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationC1 Esterase Inhibitor (Cinryze )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHereditary Angioedema: A Family Study
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2005) 23:227-233 CASE REPORT Hereditary Angioedema: A Family Study Yao-Ting Huang 1, Yung-Zen Lin 1, Hsin-Lin Wu 1, Tin-Fang Chiu 1, Kun-Mei Lee 1, Hung-Ying
More informationChronic Urticaria and Atopic Dermatitis in the Elderly
WISC 214 9 December 214 Rio de Janeiro, Brazil WAO International Scientific Conference (WISC) and the XLI (41 th ) Annual Meeting of the Brazilian Association of Allergy and Immunology (ASBAI) 22-3SY Chronic
More informationHey Hey HAE (Hereditary Angioedema) Tom Ju, M.D. Barry Nuecterlein, M.D.
Hey Hey HAE (Hereditary Angioedema) Tom Ju, M.D. Barry Nuecterlein, M.D. Case Introduction 38-year-old ASA III woman with a history of Grave s disease complicated by bilateral exophthalmos presenting for
More informationBIOBRAD Study: The Search for Biomarkers of Bradykinin-Mediated Angio-Oedema Attacks
Original Paper Received: November 17, 2015 Accepted after revision: May 17, 2016 Published online: July 30, 2016 BIOBRAD Study: The Search for Biomarkers of Bradykinin-Mediated Angio-Oedema Attacks Alban
More informationOsteosclerotic Myeloma (POEMS Syndrome)
Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Synonyms Crow-Fukase syndrome Multicentric Castleman disease Takatsuki syndrome Acronym coined by Bardwick POEMS Scheinker,
More informationHereditary angioedema (HAE) is a rare genetic disorder
Perioperative management for patients with hereditary angioedema Anesu H. Williams, D.H.Sc., M.P.A., 1 and Timothy J. Craig, D.O. 2 ABSTRACT Hereditary angioedema (HAE) is a rare autosomal dominant disease
More informationHereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity DO NOT COPY
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity Jonathan A. Bernstein, M.D., 1 Bruce Ritchie, M.D., 2 Robyn J. Levy, M.D., 3 Richard L.
More informationUrticaria and Angioedema
Urticaria and Angioedema This guideline, developed by Robbie Pesek, MD and Allison Burbank, MD, in collaboration with the ANGELS team, on July 23, 2013, is a significantly revised version of the guideline
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Cardiff SAS Porphyria Approved: Sept
More informationCase #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute
Case #1 Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute Patient History Part I 76 year-old man 1997 diagnosed with MGUS (biclonal) during evaluation of (self-limited) anemia.
More informationProphylaxis for Hereditary Angioedema with Lanadelumab and C1 Inhibitors: Effectiveness and Value
Prophylaxis for Hereditary Angioedema with Lanadelumab and C1 Inhibitors: Effectiveness and Value Revised Background and Scope May 10, 2018 Background Hereditary angioedema (HAE) is a rare genetic disorder
More informationClassification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group
POSITION PAPER Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group M. Cicardi 1, W. Aberer 2, A. Banerji 3,
More informationC1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks final results of the I.M.P.A.C.T.2 study
Allergy ORIGINAL ARTICLE SKIN AND EYE DISEASES C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks final results of the I.M.P.A.C.T.2 study T. J. Craig 1, A. K. Bewtra 2, S. L. Bahna
More informationDouglas T. Johnston, DO, FACAAI Allergy Partners of the Upstate, Greenville, SC
Faculty Mark A. Davis-Lorton, MD, FAAAAI, FACAAI Director of Clinical Immunology, Division of Rheumatology, Allergy, and Immunology, Winthrop-University Hospital, Mineola, NY Dr. Mark Davis-Lorton, after
More informationPrimary Immunodeficiency
Primary Immunodeficiency DiGeorge Syndrome Severe Combined Immunodeficiency SCID X-Linked Agammaglobulinemia Common variable immunodeficiency (CVID) IgA deficiency Hyper- IgM Syndrome Wiskott-Aldrich syndrome
More informationTHE CURRENT STATE OF MANAGEMENT OF HAE IN EUROPE
THE CURRENT STATE OF MANAGEMENT OF HAE IN EUROPE The Current State of Management of HAE in Europe Four years ago, HAEi (the international umbrella organization for the world s HAE patient groups) published
More informationPredicting Response to Omalizumab in Chronic Urticaria Based on Biomarkers
Predicting Response to Omalizumab in Chronic Urticaria Based on Biomarkers Authors: *Misbah Noshela Ghazanfar, 1 Simon Francis Thomsen 1,2 1. Department of Dermatology, Bispebjerg Hospital, Copenhagen,
More informationTHE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA
THE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA Case The patient is a 48 year-old female, who recently returned from a trip to Puerto Rico. She presents to the ED
More informationAgroup as large as 15% to 24% of
Update on Chronic Urticaria and Angioedema Sarbjit S. Saini, MD ABSTRACT PURPOSE: To review the various subtypes of angioedema and urticaria and their current standards of treatment and to highlight new
More informationabstract n engl j med 376;8 nejm.org February 23,
The new england journal of medicine established in 1812 February 23, 2017 vol. 376 no. 8 Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis A. Banerji, P. Busse, M. Shennak, W. Lumry, M.
More informationDepartment of Paediatrics Clinical Guideline URTICARIA GUIDELINE BACKGROUND
Department of Paediatrics Clinical Guideline URTICARIA GUIDELINE BACKGROUND This guideline is intended for use in A&E and general paediatric OPD to assist with the management of initial presentations of
More informationEmerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema
Bernstein and Moellman International Journal of Emergency Medicine 2012, 5:39 REVIEW Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema Jonathan A Bernstein 1*
More informationMyositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationDATE: 24 April 2015 CONTEXT AND POLICY ISSUES
TITLE: C1 Esterase Inhibitor for Prophylaxis against Hereditary Angioedema Attacks: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines DATE: 24 April 2015 CONTEXT AND POLICY ISSUES
More informationTreatment Options for Refractory Urticaria
Treatment Options for Refractory Urticaria David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology University of Texas Southwestern Medical Center
More informationKey words: antiphospholipid syndrome, trombosis, pathogenesis
26. XI,. 4/2011,.,..,..,., -..,,. 2GPI. -,.,,., -,, -, -,,,,, IL-1, IL-2, IL-6, IL-8, IL-12, IL-10, TNF, INF-. :,, N. Stoilov, R. Rashkov and R. Stoilov. ANTIPHOSPHOLIPID SYNDROME HISTORICAL DATA, ETI-
More informationThe ABCs of Waldenström s Macroglobulinemia (WM)
The ABCs of Waldenström s Macroglobulinemia (WM) Jeffrey V. Matous MD Colorado Blood Cancer Institute IWMF Ed Forum May 2017 Objectives Describe the roots underneath WM Review incidence, possible risk
More informationPracticalities of a reduced volume formulation of a C1 INH concentrate for the treatment of hereditary angioedema: real life experience
Dempster Allergy Asthma Clin Immunol (2018) 14:44 https://doi.org/10.1186/s13223-018-0267-4 Allergy, Asthma & Clinical Immunology RESEARCH Open Access Practicalities of a reduced volume formulation of
More informationPediatric hereditary angioedema due to C1-inhibitor deficiency
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY REVIEW Open Access Pediatric hereditary angioedema due to C1-inhibitor deficiency Henriette Farkas Abstract Hereditary angioedema (HAE) resulting from the deficiency
More informationMAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt.
MAF Shalaby Prof. Rheumatology Al Azhar University, Cairo, Egypt. AUTOIMMUNE DISEASE RA SLE VASCULITIS RELAPSING POLYCHONDRITIS SS DM/PM SJOGREN S SYNDROME RHEUMATOID ARTHRITIS Classically immune mediated
More informationThe Journal of Angioedemasit amet
Successful Prophylaxis of Hereditary Angioedema with Human C1 Inhibitor Concentrate: A Collection of Case Reports Isabelle Boccon-Gibod, MD 1,2,* ; Bernard Floccard, MD 2,3 ; Yann Ollivier, MD 2,4 ; Aurélie
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationA hereditary angioedema screening on an index case: Turkey
Asian Pacific Journal of Allergy and Immunology CASE STUDY A hereditary angioedema screening on an index case: Turkey Mehmet Yasar Ozkars, 1 Ozlem Keskin, 2 Nazan Bayram, 3 Mehmet Keskin, 4 Hasan Bayram,
More informationHow to Diagnose and Manage a Potentially Fatal Angioedema
Overview Mark Riedl, MD, MS, discusses how to facilitate earlier identification of patients with hereditary angioedema (HAE) through key characteristics and triggers that differentiate it from other forms
More informationAnemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017
Anemia A case-based approach David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017 Recognizing trends Learning Objectives MCV, RDW, Ferritin, LDH, Reticulocytes Managing complex patients 1.
More informationMcDuffy's Hypocomplementemic Urticarial Vasculitis: A New Observation
Human Journals Case Report December 2017 Vol.:8, Issue:2 All rights are reserved by N. Boussetta et al. McDuffy's Hypocomplementemic Urticarial Vasculitis: A New Observation Keywords: Urticaria, vasculitis,
More informationPediatric hereditary angioedema
The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation MacGinnitie, Andrew J. 2013.. Pediatric Allergy and Immunology 25 (5):
More informationPatterns of Lymphoid Neoplasia in Peripheral Blood. Leon F. Baltrucki, M.D. Leon F. Baltrucki, M.D. Disclosure
Patterns of Lymphoid Neoplasia in Peripheral Blood Leon F. Baltrucki, M.D. Leon F. Baltrucki, M.D. Disclosure Dr Baltrucki has received an honorarium for his participation as a faculty presenter in this
More informationAngioedema: beyond histamine. Didier EBO Immunology Allergology - Rheumatology. seminaires iris
Angioedema: beyond histamine Didier EBO Immunology Allergology - Rheumatology Phadia ThermoFisher Scientific BD Biosciences Shire / CAF Conflict of interest Clinics Causes & pathogenesis Drug therapy (incl.
More informationMonoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH
Monoclonal Gammopathies and the Kidney Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal gammopathy of renal significance (MGRS) Biopsies at OSU (n=475) between 2007 and 2016 AL or AH
More informationImmunology. Lecture- 8
Immunology Lecture- 8 Immunological Disorders Immunodeficiency Autoimmune Disease Hypersensitivities Immunodeficiency 1. Immunodeficiency --> abnormal production or function of immune cells, phagocytes,
More informationC1 inhibitor deficiency in. vascular permeability defect in HAE.
A CME-Accredited Newsletter Advances in Hereditary Angioedema Treatment Considerations, Criteria, and the New Therapy Options for Treatment and Prevention of HAE Attacks At a symposium conducted in conjunction
More informationClinical Commissioning Policy Proposition: Rituximab for cytopaenia complicating primary immunodeficiency
Clinical Commissioning Policy Proposition: Rituximab for cytopaenia complicating primary immunodeficiency Reference: NHS England F06X02/01 Information Reader Box (IRB) to be inserted on inside front cover
More informationUPDATES ON PEDIATRIC SLE
UPDATES ON PEDIATRIC SLE BY ANGELA MIGOWA, PEDIATRIC RHEUMATOLOGIST/SENIOR INSTRUCTOR AKUHN MBCHB-UON, MMED-AKUHN,PEDIATRIC RHEUMATOLOGY- MCGILL UNIVERSITY HEALTH CENTRE ROSA PARKS OBJECTIVES RECOGNIZE
More informationAssessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy
Assessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy Tolly Epstein, MD, MS Assistant Professor of Clinical Medicine Division of Immunology, Allergy & Rheumatology University
More informationFOR PUBLIC CONSULTATION ONLY RITUXIMAB FOR CYTOPENIA FROM PRIMARY IMMUNE DEFICIENCY
RITUXIMAB FOR CYTOPENIA FROM PRIMARY IMMUNE DEFICIENCY QUESTION(S) TO BE ADDRESSED: What is the evidence for the clinical and cost effectiveness for rituximab for the management of auto-immune cytopenia
More informationDalazatide, first-in-class Kv1.3 channel blocker, an immunomodulators journey from sea to clinic
Dalazatide, first-in-class Kv1.3 channel blocker, an immunomodulators journey from sea to clinic Aurora Biomed Ion Channels Retreat 2015 Shawn Iadonato Dalazatide: Potential Autoimmune Blockbuster Immune
More informationQJM Advance Access published January 21, 2015 BIG LIPS. M. Reveillon, V. Eble, H. Levesque, I. Marie
QJM Advance Access published January 21, 2015 BIG LIPS M. Reveillon, V. Eble, H. Levesque, I. Marie Mathilde Reveillon, MD; Vincent Eble, MD; Hervé Levesque MD, PhD; Isabelle Marie, MD, PhD. Department
More informationMechanisms of Autontibodies
Mechanisms of Autontibodies Production in Rheumatic Diseases Eisa Salehi PhD Tehran University of Medical Sciences Immunology Department Introduction Rheumatic diseases: Cause inflammation, swelling, and
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More information4/12/18. Refractory Chronic Urticaria: When Omalizumab Fails. Objectives. Disclosures
Refractory Chronic Urticaria: When Omalizumab Fails David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures n Research Grants n NIH n Honoraria n UpToDate,
More informationHow to Successfully Manage Chronic Urticaria? & Tall Tales from Texas
How to Successfully Manage Chronic Urticaria? & Tall Tales from Texas David A. Khan, MD Professor of Medicine and Pediatrics Allergy & Immunology Program Director 1 Disclosures Honoraria/Speakers Bureau
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationAllergy and Immunology Review Corner: Chapter 57 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 57 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 57: Insect Allergy Pages 1005-1017 Prepared
More informationClementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 2
Clinical Medicine Insights: Blood Disorders Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. C1 Esterase Inhibitor (Human) for the Treatment of Acute
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationRoche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma
Media Release Basel, 12 January 2017 Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Administration time significantly reduced
More information3302: Therapy Options for Patients with Anti-Histamine Resistant Chronic Urticaria
3302: Therapy Options for Patients with Anti-Histamine Resistant Chronic Urticaria Javed Sheikh, M.D. FAAAI Department of Allergy & Clinical Immunology Kaiser Permanente Los Angeles Medical Center Disclosure
More informationJonathan Katz, MD CPMC
Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC First, a bit of background Classic CIDP--TREATABLE MADSAM/Asymmetric Neuropathy Chronic Length Dependent Neuropathy-
More informationCoagulation Factor XII Gene Mutation in Brazilian Families with Hereditary Angioedema with Normal C1 Inhibitor
Original Paper Received: May 28, 204 Accepted after revision: January 28, 205 Published online: March 3, 20 5 Coagulation Factor XII Gene Mutation in Brazilian Families with Hereditary Angioedema with
More informationI Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015
I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015 Larry Anderson, MD, PhD Plasma Cell Disorder and Stem Cell Transplant Specialist UT Southwestern Medical
More informationAutoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic
Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration
More informationIdiopathic Anaphylaxis. Paul A. Greenberger, MD, FAAAAI 2/28/2014 Course # 1605
Idiopathic Anaphylaxis Paul A. Greenberger, MD, FAAAAI 2/28/2014 Course # 1605 Objectives Review definition and classification of idiopathic anaphylaxis Consider the differential diagnosis Critique lab
More informationEvaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study
Accepted: 12 April 2018 DOI: 10.1111/all.13466 ORIGINAL ARTICLE Skin and Eye Disease Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2
More informationAutoimmunity and Primary Immune Deficiency
Autoimmunity and Primary Immune Deficiency Mark Ballow, MD Division of Allergy & Immunology USF Morsani School of Medicine Johns Hopkins All Children s Hospital St Petersburg, FL The Immune System What
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationWhich Factors Might Enhance Safety of Immunotherapy in Your Clinic?
Which Factors Might Enhance Safety of Immunotherapy in Your Clinic? David I. Bernstein MD FAAAI Professor of Medicine and Environmental Health Division of Immunology and Allergy University of Cincinnati
More informationUmbrella study design in patients with Hereditary Periodic Fevers, an orphan autoimmune disease. Karine Lheritier 15 June 2016 PSI Immunology meeting
Umbrella study design in patients with Hereditary Periodic Fevers, an orphan autoimmune disease Karine Lheritier 15 June 2016 PSI Immunology meeting Outline Hereditary Periodic Fevers Canakinumab Study
More informationClinical Pattern and Acute and Long-term Management of Hereditary Angioedema Due to C1-Esterase Inhibitor Deficiency
ORIGINAL ARTICLE Clinical Pattern and Acute and Long-term Management of Hereditary Angioedema Due to C1-Esterase Inhibitor Deficiency Gómez-Traseira C 1,4, Pérez-Fernández E 2,4, López-Serrano MC 1,4,5,
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationDiagnosis and management of angioedema with abdominal involvement: A gastroenterology perspective
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v16.i39.4913 World J Gastroenterol 2010 October 21; 16(39): 4913-4921 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationAcquired Inhibitors of Coagulation
Acquired Inhibitors of Coagulation Christine L Kempton, MD, MSc Emory University Disclosures for In compliance with COI policy, ISTH requires the following disclosures to the session audience: Research
More informationThe international WAO/EAACI guideline for the management of hereditary angioedema The 2017 revision and update
Accepted: 12 December 2017 DOI: 10.1111/all.13384 POSITION PAPER The international WAO/EAACI guideline for the management of hereditary angioedema The 2017 revision and update M. Maurer 1 M. Magerl 1 I.
More informationInteresting Case Series. Skin Grafting in Pyoderma Gangrenosum
Interesting Case Series Skin Grafting in Pyoderma Gangrenosum Marco Romanelli, MD, PhD, Agata Janowska, MD, Teresa Oranges, MD, and Valentina Dini, MD, PhD Department of Dermatology, University of Pisa,
More information